Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Thomas Kaley et al.|Nature Genetics|2019Cited by 4.4k
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapyChristopher A. Klebanoff, Nicholas P. Restifo|JCI Insight|2017Cited by 221
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CASmita S. Chandran, Christopher A. Klebanoff|Nature Medicine|2022Cited by 126
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancerAndrew Chow, Charles M. Rudin, Fathema Uddin et al.|Immunity|2022Cited by 123
Immunogenicity of a public neoantigen derived from mutated <i>PIK3CA</i>Smita S. Chandran, Christopher A. Klebanoff|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 3